Amarin Corp Plc (AMRN)

[JB_Biotech]

Unlikely. Generics can compete with Vascepa because physicians can substitute Vascepa prescriptions gor identical generic products. Generic vascepa would be proven to lower CV Risk (Reduce-It label) although generics cannot promote it’s CV lowering effects. I highly doubt than an unproven EPA Would be substituted for Vascepa/generic Vascepa in CV prescriptions. Too much risk for physicians, if proven generics exist